Silka Cream Availability: What Providers and Prescribers Need to Know in 2026

Silka Antifungal Cream is an over-the-counter terbinafine hydrochloride 1% product that many clinicians recommend for dermatophyte infections of the skin. While there is no active FDA shortage in 2026, providers should be aware of real-world access challenges that patients encounter — and how to counsel them effectively.

Clinical Overview: What Is Silka Cream?

Silka Antifungal Cream is an OTC allylamine antifungal containing 1% terbinafine hydrochloride. Allylamines work by inhibiting squalene epoxidase, an enzyme involved in ergosterol biosynthesis. The resulting depletion of ergosterol and accumulation of squalene are fungicidal — unlike azoles and tolnaftate, which are primarily fungistatic.

Terbinafine topical is FDA-approved for:

• Tinea pedis (athlete's foot) — between toes: 1 week BID; bottom/sides of foot: 2 weeks BID
• Tinea cruris (jock itch) — 1 week once daily
• Tinea corporis (ringworm) — 1 week once daily

It is not indicated for tinea unguium (onychomycosis), tinea capitis, or Candida infections. For nail fungus, oral terbinafine (Rx) is appropriate. For scalp infections or candidal intertrigo, azole agents are preferred.

Current Availability Status in 2026

As of 2026, Silka Cream is not listed in the FDA Drug Shortages Database, and no formal shortage has been declared by Genomma Lab USA, Inc., the distributor. Terbinafine 1% topical cream is produced by multiple manufacturers and is commercially available through major retail channels.

However, clinicians should counsel patients that Silka as a specific brand may not be stocked at every pharmacy. The product is primarily distributed through large national retailers (Walmart, CVS, Walgreens, Amazon). Patients at independent or rural pharmacies may not have access to the Silka brand specifically, though therapeutically equivalent generics are widely available.

Patient Access Challenges Clinicians Should Know

Several access-related issues commonly arise in practice:

• Brand familiarity confusion. Patients may be brand-loyal to Silka and refuse to substitute even when generic terbinafine 1% is on the shelf. Proactive counseling that any 1% terbinafine cream is therapeutically equivalent can prevent unnecessary treatment delays.
• Insurance coverage. As an OTC product, Silka Cream is generally not covered by most insurance plans. However, it is FSA- and HSA-eligible. Patients with high-deductible plans often benefit from knowing this. For patients who require prescription-strength terbinafine cream (e.g., immunocompromised patients or atypical presentations), a written prescription for terbinafine 1% cream may allow partial coverage under some plans.
• Seasonal unavailability. Demand peaks in summer and early fall. During these periods, some stores may be temporarily sold out. Advising patients to check multiple stores or order online reduces treatment delays.
• Age restriction. OTC terbinafine products, including Silka, are labeled for adults and children 12 years of age and older. For pediatric patients under 12 years, a consultation with a physician and potentially a compounded or alternative treatment may be needed.

Clinical Alternatives When Terbinafine Topical Is Unavailable

When OTC terbinafine is unavailable or clinically inappropriate, consider these evidence-based alternatives:

• Butenafine 1% (Lotrimin Ultra, OTC): Another allylamine antifungal; fungicidal; comparable efficacy for tinea pedis (interdigital). Treatment: 1 week BID for tinea pedis (toes); 2 weeks QD for tinea cruris and tinea corporis.
• Clotrimazole 1% (Lotrimin AF, OTC): Azole antifungal; fungistatic; broader coverage including Candida. Use for 4 weeks (tinea pedis, tinea corporis) or 2 weeks (tinea cruris). Preferred for sensitive skin or Candidal intertrigo.
• Econazole 1% (Rx): Prescription azole with broad antifungal activity; suitable for cases not responding to OTC options.
• Luliconazole 1% cream (Luzu, Rx): Newer imidazole with potent activity against dermatophytes; once-daily dosing; good option for patients with adherence challenges.

When Should Clinicians Recommend Prescription vs. OTC Treatment?

OTC terbinafine cream (including Silka) is appropriate first-line treatment for mild to moderate tinea pedis, tinea cruris, and tinea corporis in immunocompetent patients 12 and older. Prescription treatment should be considered when:

• Infection fails to respond to a full OTC course
• Extensive or widely distributed infection is present
• Onychomycosis is suspected or confirmed (requires oral terbinafine 250 mg daily for 6–12 weeks, Rx only)
• Patient is immunocompromised, has diabetes, or has peripheral vascular disease
• Tinea capitis is the diagnosis (requires oral antifungal; topical alone is insufficient)

How medfinder Can Support Your Patients

For clinicians whose patients struggle to locate Silka Cream or any OTC or prescription medication locally, medfinder for providers offers a service that calls pharmacies near the patient to find which locations have a medication in stock, then texts the patient the results. This reduces unnecessary callbacks and patient frustration when they can't find their medication.

Read our related guide: How to Help Your Patients Find Silka Cream in Stock.